This advisory highlights more than 100 poster abstracts that will be presented at ASH 2025 involving researchers ...

Ulcerative colitis is a chronic, immune-mediated disorder of the colon, which is characterised by a relapsing–remitting course. Owing to the growing understanding of the immunopathogenesis of this ...

Although penile cancer represents less than 1% of male malignancies, it carries substantial physical and psychological burden ...

Third Arc Bio is paying $5 million upfront to use Adagene’s tech in hopes of creating two new masked T-cell engagers. | Third ...

Authorization Received from UK and EU Authorities to Activate ex-US Clinical Trial Sites Supporting the Ongoing Patient ...

Presented new subgroup analyses from phase 3 clinical trial of CAN-2409 in localized prostate cancer at the American Society for Radiation Oncology (ASTRO) 2025 meeting, demonstrating improved ...

Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies for cancer, today announced the publication of a peer-reviewed study titled "Antibody?Gamma/Delta T ...

Using a single-cell RNA-sequencing platform, a new study demonstrates that EBV reprograms autoreactive B cells to drive lupus autoimmunity.

A new study has finally nailed down what links Epstein-Barr virus (EBV) – a pathogen that over 95 percent of adults worldwide ...

Oral presentation of Lynozyfic™ (linvoseltamab-gcpt) data in newly diagnosed multiple myeloma from LINKER-MM4, the first trial to evaluate a BCMAxCD3 bispecific antibody as a monotherapy in this ...

Barr virus transforms B cells into inflammatory drivers that spark the widespread immune attacks seen in lupus.